Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy

Autor: Gregory R. Pond, Giuseppe Di Lorenzo, Richard T. Lee, Matthew D. Galsky, Piera Federico, Raju Titus Chacko, Jatinder Goyal, Mollie deShazo, Bernhard J. Eigl, Graeme B. Bolger, Michael Kolinsky, Tanya B. Dorff, Andrea Necchi, Guru Sonpavde, Lauren C. Harshman, Amitkumar Mehta, Matthew I. Milowsky

Publikováno v: Urologic Oncology: Seminars and Original Investigations. 32:501-508

Background: Prognostic factors in men with penile squamous cell carcinoma (PSCC) receiving systemic therapy are unknown. A prognostic classification system in this disease may facilitate interpretation of outcomes and guide rational drug development.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::350fd568c4644963df3b5985b967633a
https://doi.org/10.1016/j.urolonc.2013.10.007

A Real World Observational Study Characterizing Patients With Advanced Prostate Cancer Treated With or Without Androgen Receptor-Pathway-Inhibitor Therapies in Alberta, Canada.

Autor: O'Sullivan DE; Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary Alberta, Canada., Kolinsky MP; Department of Oncology, University of Alberta, Edmonton, Alberta, Canada., Shokar S; AstraZeneca Canada, Mississauga, Ontario, Canada., Jarada TN; Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary Alberta, Canada., Cheung WY; Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary Alberta, Canada. Electronic address: Winson.cheung@albertahealthservices.ca.

Publikováno v: Clinical genitourinary cancer [Clin Genitourin Cancer] 2024 Oct; Vol. 22 (5), pp. 102115. Date of Electronic Publication: 2024 May 09.

Genetic testing practices among specialist physicians who treat prostate cancer A Canadian, cross-sectional survey.

Autor: Yip SM; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada., Morash C; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada., Kolinsky MP; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada., Kapoor A; St Joseph's Healthcare, McMaster University, Hamilton, ON, Canada., Ong M; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada., Selvarajah S; Department of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network (UHN), Toronto, ON, Canada.; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada., Nuk J; Hereditary Cancer Program, BC Cancer, Vancouver, BC, Canada., Compton K; Hereditary Cancer Program, BC Cancer, Vancouver, BC, Canada., Pouliot F; Centre hospitalier universitaire de Québec, Université Laval, Quebec City, QC, Canada., Lavallée LT; Division of Urology, Department of Surgery, University of Ottawa and Ottawa Hospital Research Institute Epidemiology Program, Ottawa, ON, Canada., Khalaf DJ; Department of Medicine, Medical Oncology Division, BC Cancer, Vancouver Centre, University of British Columbia, Vancouver, BC, Canada., Hamilton RJ; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada., Gotto GT; Southern Alberta Institute of Urology, University of Calgary, Calgary, AB, Canada., Rendon RA; Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS, Canada., Antebi E; Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA., Hotte SJ; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada., Malone S; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada., Chi KN; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada., Drachenberg DE; Section of Urology, Department of Surgery, University of Manitoba, Winnipeg, MB, Canada., Saad F; Centre Hospitalier de l'Université de Montréal, University of Montreal, Montreal, QC, Canada., Chan J; Scarborough Health Network, University of Toronto, ON, Canada., Ferrario C; Jewish General Hospital, McGill University, Montreal, QC, Canada., Ko J; Department of Medical Oncology, BC Cancer - Abbotsford, Abbotsford, BC, Canada., Shayegan B; St Joseph's Healthcare, McMaster University, Hamilton, ON, Canada., Parimi S; Department of Medical Oncology, BC Cancer-Victoria, BC, Canada., So AI; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada., Feifer A; Division of Urology, Department of Surgery, University of Toronto, Toronto, ON Canada.; Institute for Better Health, Trillium Health Partners, Mississauga, ON Canada., Jansz K; Joseph Brant Hospital, McMaster University, Burlington, ON, Canada., Finch D; Department of Medical Oncology, BC Cancer Agency - Centre for the Southern Interior, Kelowna, BC, Canada., Chin JL; Department of Surgery (Urology), University of Western Ontario, London Health Sciences Center, London, ON, Canada., Osborne B; Medical Affairs, Janssen Inc, Toronto, ON, Canada., Ho KF; STAT-TU Inc., Elora, ON, Canada., Galamo CD; Medical Affairs, Janssen Inc, Toronto, ON, Canada., Zardan A; Medical Affairs, Janssen Inc, Toronto, ON, Canada., Niazi T; Jewish General Hospital, McGill University, Montreal, QC, Canada.

Publikováno v: Canadian Urological Association journal = Journal de l'Association des urologues du Canada [Can Urol Assoc J] 2023 Oct; Vol. 17 (10), pp. 326-336.

Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26].

Autor: Yu EY; University of Washington and Fred Hutchinson Cancer Center, Seattle, WA, USA. Electronic address: evanyu@u.washington.edu., Piulats JM; Catalan Institute of Oncology, Barcelona, Spain., Gravis G; Institut Paoli Calmettes, Marseille, France., Fong PCC; Auckland City Hospital, Auckland, New Zealand; University of Auckland, Auckland, New Zealand., Todenhöfer T; Studienpraxis Urologie, Nürtingen, Germany., Laguerre B; Centre Eugène Marquis, Rennes, France., Arranz JA; General University Hospital Gregorio Marañón, Madrid, Spain., Oudard S; Hôpital Européen Georges Pompidou, University of Paris, Paris, France., Massard C; Gustave Roussy, Cancer Campus, Villejuif, France; Paris-Saclay University, Villejuif, France., Heinzelbecker J; Saarland University Medical Center, Homburg, Germany; Faculty of Medicine, Saarland University, Homburg, Germany., Nordquist LT; GU Research Network-Urology Cancer Center, Omaha, NE, USA., Carles J; Vall d'Hebron Institute of Oncology, Vall d'Hebron, Barcelona, Spain., Kolinsky MP; Cross Cancer Institute and University of Alberta, Edmonton, AB, Canada., Augustin M; Paracelsus Medical University, Nuremberg, Germany., Gurney H; Macquarie University, Sydney, Australia., Tafreshi A; University of Wollongong, Wollongong, NSW, Australia., Li XT; Merck & Co., Inc., Rahway, NJ, USA., Qiu P; Merck & Co., Inc., Rahway, NJ, USA., Poehlein CH; Merck & Co., Inc., Rahway, NJ, USA., Schloss C; Merck & Co., Inc., Rahway, NJ, USA., de Bono JS; The Institute of Cancer Research and the Royal Marsden, London, UK.

Publikováno v: European urology [Eur Urol] 2023 Mar; Vol. 83 (3), pp. e87. Date of Electronic Publication: 2022 Dec 15.

Recommendations for the implementation of genetic testing for metastatic prostate cancer patients in Canada.

Autor: Selvarajah S; Department of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network (UHN), Toronto, ON, Canada.; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada., Schrader KA; Department of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.; Hereditary Cancer Program, BC Cancer, Vancouver, BC, Canada., Kolinsky MP; Cross Cancer Institute and Department of Oncology, University of Alberta, Edmonton, AB, Canada., Rendon RA; Department of Urology, Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada., El Hallani S; Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada., Fleshner NE; Division of Urology, Departments of Surgery and Surgical Oncology, University Health Network, Toronto, ON, Canada., Hotte SJ; Department of Oncology, McMaster University, Hamilton, ON, Canada., Lorentz J; Genetics and High Risk Program, Sunnybrook Health Sciences Centre, Toronto, ON, Canada., Panabaker K; Medical Genetics Program of Southwestern Ontario, London Health Sciences Centre, London, ON, Canada., Perrier R; Department of Medical Genetics, Alberta Children's Hospital and Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Pouliot F; Divison of Urology, Department of Surgery, CHU de Québec and Laval University, Quebec, QC, Canada., Spatz A; Department of Laboratory Medicine, McGill University Health Centre, Department of Pathology, McGill University, Research Molecular Pathology Center, Lady Davis Institute, Montreal, QC, Canada., Yip S; Department of Pathology & Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada., Chi KN; BC Cancer, Vancouver, BC, Canada.

Publikováno v: Canadian Urological Association journal = Journal de l'Association des urologues du Canada [Can Urol Assoc J] 2022 Oct; Vol. 16 (10), pp. 321-332.